Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XL999 in Recurrent Ovarian Cancer
NCT00277290Phase 2Terminated
- Sponsor
- Symphony Evolution
- Start
- Jan 2006
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of xl999 in ovarian cancer, sponsored by Symphony Evolution. Started Jan 2006; status: terminated.
02
Drugs
xl999
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00277290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277290.